Charlottesville, VA1 Active Studies

Neuroendocrine Tumors Clinical Trials in Charlottesville, VA

Find 1 actively recruiting neuroendocrine tumors clinical trials in Charlottesville, VA. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
440
Enrolling

Recruiting Neuroendocrine Tumors Studies in Charlottesville

About Neuroendocrine Tumors Clinical Trials in Charlottesville

Neuroendocrine tumors (NETs) develop from hormone-producing cells and can occur in many organs, most commonly the gastrointestinal tract and lungs. They range from slow-growing to aggressive. Treatment includes surgery, somatostatin analogs, targeted therapy, and peptide receptor radionuclide therapy.

There are currently 1 neuroendocrine tumors clinical trials recruiting participants in Charlottesville, VA. These studies are seeking a combined 440 participants. Research is being sponsored by Exelixis. Clinical trial participation is free and participants receive study-related medical care at no cost.

Neuroendocrine Tumors Clinical Trials in Charlottesville — FAQ

Are there neuroendocrine tumors clinical trials in Charlottesville?

Yes, there are 1 neuroendocrine tumors clinical trials currently recruiting in Charlottesville, VA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Charlottesville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Charlottesville research site will contact you about next steps.

Are clinical trials in Charlottesville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Charlottesville studies also compensate for your time and travel.

What neuroendocrine tumors treatments are being tested?

The 1 active trials in Charlottesville are testing new therapies including novel drugs, biologics, and treatment approaches for neuroendocrine tumors.

Data updated March 2, 2026 from ClinicalTrials.gov